Lọc theo
A healthy lifestyle pattern, especially maintaining a healthy weight, may lower the risk of developing symptomatic gallstone diseases, as indicated by findings from two large prospective studies.
Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.
Drinking coffee, tea, or soda may trigger gastroesophageal reflux, whereas water, juice, or milk does not, according to a study.
Safety data from the phase III IMbrave150 trial reinforce the previously reported favourable safety profile of atezolizumab-bevacizumab compared with sorafenib for unresectable hepatocellular carcinoma (HCC).
